Improving cognitive functioning in major depressive disorder with psychedelics: A dimensional approach
Open accessThe DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Abstract
The high symptomatic and biological heterogeneity of major depressive disorder (MDD) makes it very difficult to find broadly efficacious treatments that work against all symptoms. Concentrating on single core symptoms that are biologically well understood might consist of a more viable approach. The Research Domain Criteria (RDoC) framework is a trans-diagnostic dimensional approach that focuses on symptoms and their underlying neurobiology. Evidence is accumulating that psychedelics may possess antidepressant activity, and this can potentially be explained through a multi-level (psychobiological, circuitry, (sub)cellular and molecular) analysis of the cognitive systems RDoC domain. Cognitive deficits, such as negative emotional processing and negativity bias, often lead to depressive rumination. Psychedelics can increase long-term cognitive flexibility, leading to normalization of negativity bias and reduction in rumination. We propose a theoretical model that explains how psychedelics can reduce the negativity bias in depressed patients. At the psychobiological level, we hypothesize that the negativity bias in MDD is due to impaired pattern separation and that psychedelics such as psilocybin help in depression because they enhance pattern separation and hence reduce negativity bias. Pattern separation is a mnemonic process that relies on adult hippocampal neurogenesis, where similar inputs are made more distinct, which is essential for optimal encoding of contextual information. Impairment in this process may underlie the negative cognitive bias in MDD by, for example, increased pattern separation of cues with a negative valence that can lead to excessive deliberation on aversive outcomes. On the (sub) cellular level, psychedelics stimulate hippocampal neurogenesis as well as synaptogenesis, spinogenesis and dendritogenesis in the prefrontal cortex. Together, these effects help restoring resilience to chronic stress and lead to modulation of the major connectivity hubs of the prefrontal cortex, hippocampus, and amygdala. Based on these observations, we propose a new translational framework to guide the development of a novel generation of therapeutics to treat the cognitive symptoms in MDD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 3×
“Preliminary evidence supports long-term positive effects of serotonergic psychedelics on symptoms of depression in patients with MDD, treatment-resistant depression, and life-threatening cancer with depression (Griffiths et al., 2016; Carhart-Harris et al., 2016a; Carhart-Harris et al., 2018a; Davis et al., 2020; Dos…”
BackgroundResting-state connectivity biomarkers define neurophysiological subtypes of depression
Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R. N., Zebley, B., Oathes, D. J., Etkin, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4246 · Cited by 2,170 · cited 1×
“For the diagnosis of MDD, five of nine different symptoms described in the DSM need to be present (Drysdale et al., 2017), including one of two core symptoms: depressed mood or anhedonia.”
BackgroundPrevalence of depression symptoms in US adults before and during the COVID-19 pandemic
Ettman, C. K., Abdalla, S. M., Cohen, G. H., Sampson, L., Vivier, P. M., & Galea, S. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.19686 · Cited by 2,138
The global burden of mental disorders: An update from the WHO World Mental Health (WMH) surveys
Kessler, R. C., Aguilar-Gaxiola, S., Alonso, J., Chatterji, S., Lee, S., Ormel, J., Üstün, T. B., & Wang, P. S. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00001421 · Cited by 1,895
Emotion and Cognition: Insights from Studies of the Human Amygdala
Phelps, E. A. (2006) · Annual Review of Psychology · doi:10.1146/annurev.psych.56.091103.070234 · Cited by 1,798 · cited 1×
“The amygdala has a central role in fear perception and emotional processing, which explains its association with mood and anxiety disorders, including MDD (Phelps, 2006).”
BackgroundStress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“BDNF is believed to be a prime mediator of neuroplasticity (Banasr, Dwyer, & Duman, 2011; Pittenger & Duman, 2008).”
BackgroundNichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016) · Nature Medicine · doi:10.1038/nm.4050 · Cited by 1,750 · cited 5×
“The cognitive model of depression was first introduced by Aaron Beck (1963).”
BackgroundInfluentialNeural mechanisms of the cognitive model of depression.
Disner, S. G., Beevers, C. G., Haigh, E. A. P., & Beck, A. T. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3027 · Cited by 1,718 · cited 2×
“Moreover, the negativity bias has been linked to behavioural, affective, somatic, and motivational symptoms of depression (Disner et al., 2011).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
A Functional Role for Adult Hippocampal Neurogenesis in Spatial Pattern Separation
Clelland, C. D., Choi, M., Romberg, C., Clemenson, G. D., Fragniere, A., Tyers, P., Jessberger, S., Saksida, L. M., Barker, R. A., Gage, F. H., et al. (2009) · Science · doi:10.1126/science.1173215 · Cited by 1,642
Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation
Sahay, A., Scobie, K. N., Hill, A. S., O'Carroll, C. M., Kheirbek, M. A., Burghardt, N. S., Fenton, A. A., Dranovsky, A., & Hen, R. (2011) · Nature · doi:10.1038/nature09817 · Cited by 1,567 · cited 1×
“In this mnemonic process, similar inputs are made more distinct (Clelland et al., 2009; Sahay et al., 2011) which is essential for optimal encoding of contextual information to ensure that new experiences are stored without overlapping or interfering with those previously encoded.”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Adult hippocampal neurogenesis buffers stress responses and depressive behaviour
Snyder, J. S., Soumier, A., Brewer, M., Pickel, J., & Cameron, H. A. (2011) · Nature · doi:10.1038/nature10287 · Cited by 1,473 · cited 1×
“Finally, impaired pattern separation may affect processing of cue contingency relationships and abnormal perception of salience and reward resulting in increased anxiety and anhedonia (Snyder et al., 2011).”
BackgroundThinking and Depression: I. Idiosyncratic Content and Cognitive Distortions
BECK, A. T. (1963) · Archives of General Psychiatry · doi:10.1001/archpsyc.1963.01720160014002 · Cited by 1,308
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301 · cited 2×
“Preliminary evidence supports long-term positive effects of serotonergic psychedelics on symptoms of depression in patients with MDD, treatment-resistant depression, and life-threatening cancer with depression (Griffiths et al., 2016; Carhart-Harris et al., 2016a; Carhart-Harris et al., 2018a; Davis et al., 2020; Dos…”
BackgroundPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Adult hippocampal neurogenesis in depression
Sahay, A., & Hen, R. (2007) · Nature Neuroscience · doi:10.1038/nn1969 · Cited by 1,206 · cited 2×
“Based on this evidence, a role for pattern separation has been proposed in antidepressant action (Sahay and Hen, 2007).”
BackgroundMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205 · cited 1×
“Like psychedelics, there is strong evidence showing that the underlying mechanism of these effects involves the stimulation of cortical neuroplasticity and hippocampal neurogenesis (Ly et al., 2018, 2020; Murrough et al., 2013).”
BackgroundREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172
Neurogenesis in the adult hippocampus
Kempermann, G., Song, H., & Gage, F. H. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a018812 · Cited by 1,072
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“The first was an open-label study by Carhart-Harris, Bolstridge, et al. (2016) and Carhart-Harris et al. (2018) where the antidepressant effects of a double dose of psilocybin, administered 1 week apart in supportive settings, were observed in a subpopulation of twenty patients with…”
BackgroundDepressive rumination, the default-mode network, and the dark matter of clinical neuroscience
Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.020 · Cited by 952 · cited 2×
“In line with this functions, increased baseline activity of the DMN has been associated to depressive rumination (Hamilton et al., 2012, 2015).”
BackgroundHamilton, J. P., Etkin, A., Furman, D. J., Lemus, M. G., Johnson, R. F., & Gotlib, I. H. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.11071105 · Cited by 866
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Roseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
The neurobiology of depression: An integrated view
Dean, J., & Keshavan, M. (2017) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2017.01.025 · Cited by 765 · cited 1×
“In fact, depression derives from the neuropathological connections between these areas, namely the PFC, the hippocampus, and the amygdala (Dean & Keshavan, 2017).”
BackgroundNeuroplasticity in cognitive and psychological mechanisms of depression: an integrative model
Price, R. B., & Duman, R. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0615-x · Cited by 739 · cited 2×
“This is in line with the idea that neural cell survival, proliferation and plasticity are essential for various cognitive processes because they maintain and update neural connection in important cognitive circuitries (Price & Duman, 2020).”
BackgroundThe neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“This class of compounds includes lysergic acid diethylamide (LSD), n,ndimethyltryptamine (DMT), and psilocybin, which act as (non-selective) agonists at the serotonin 2a receptor (5-HT2AR) (Ray, 2010; Vollenweider & Kometer, 2010).”
BackgroundThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706 · cited 1×
“…processing of sensory stimuli that leads to the well-known visual hallucinations, the acute subjective effects of psychedelics include reduction in rigid thinking, enhancement of environmental sensitivity and emotional release (Carhart-Harris & Goodwin, 2017; Madsen et al., 2019; Nichols, 2016).”
BackgroundMolendijk, M. L., Spinhoven, P., Polak, M., Bus, B. A. A., Penninx, B. W. J. H., & Elzinga, B. M. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.105 · Cited by 702 · cited 1×
“Yet, the lower BDNF protein levels and altered epigenetic regulation observed in the blood of MDD patients suggest an overall net reduction of its signalling (Kurita, Nishino, Kato, Numata, & Sato, 2012; Molendijk et al., 2011, 2014; Van den Berg et al., 2020).”
The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex
Liu, W., Ge, T., Leng, Y., Pan, Z., Fan, J., Yang, W., & Cui, R. (2017) · Neural Plasticity · doi:10.1155/2017/6871089 · Cited by 640 · cited 1×
“Post mortem human imaging studies, as well as animal studies, suggest that the atrophy of neurons in these areas, as observed by the loss of dendritic spines, neurites and synapses, play a key role in the pathophysiology of cognitive dysfunctions observed in MDD (Liu et al., 2017).”
MethodPsilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · doi:10.1101/2021.02.17.431629 · Cited by 628 · cited 1×
“For example, preclinical studies an increase in neurito-, synapto-, and spino-genesis in frontocortical neurons both in vitro and in vivo (Ly et al., 2018, 2020; Shao et al., 2021, preprint).”
Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo
Shao, L.-X., Liao, C., Gregg, I., Davoudian, P. A., Savalia, N. K., Delagarza, K., & Kwan, A. C. (2021) · Neuron · doi:10.1016/j.neuron.2021.06.008 · Cited by 626
Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587 · cited 1×
“…colleagues found an association between the long-term antidepressant effects of psilocybin in MDD and changes in resting state functional connectivity (RSFC) between brain areas of the DMN involved in processes of cognitive flexibility, such as attention and memory (Carhart-Harris et al., 2017).”
BackgroundPsychedelic drugs: neurobiology and potential for treatment of psychiatric disorders
Vollenweider, F. X., & Preller, K. H. (2020) · Nature Reviews Neuroscience · doi:10.1038/s41583-020-0367-2 · Cited by 570
Madsen, M. K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0324-9 · Cited by 517 · cited 2×
“The 5-HT2AR is widely expressed throughout the cortex (Beliveau et al., 2017), and is the primary mediator of the acute subjective effects of psychedelics on cognition (Madsen et al., 2019; Nichols, 2016; Preller et al., 2017).”
BackgroundHartogsohn, I. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116677852 · Cited by 483 · cited 2×
“The quality of this experience is known to be strongly dependent on stimuli generating internally and externally, which are commonly known as “set” and “setting” (Hartogsohn, 2016).”
A non-hallucinogenic psychedelic analogue with therapeutic potential
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., et al. (2021) · Nature · doi:10.1038/s41586-020-3008-z · Cited by 473 · cited 1×
“Based on the lack of head twitch responses observed in mice after administration, the latter being a validated measure for the hallucinogenic property of drugs, Olson and colleagues claimed to have developed such compounds (Cameron et al., 2021; Olson, 2020).”
BackgroundDendritic structural plasticity and neuropsychiatric disease
Forrest, M. P., Parnell, E., & Penzes, P. (2018) · Nature Reviews Neuroscience · doi:10.1038/nrn.2018.16 · Cited by 464 · cited 1×
“In MDD, a reduction of neuroplasticity in the PFC and hippocampus is observed as a reduction of dendritic arbors and spine density in pyramidal neurons (Forrest et al., 2018).”
BackgroundThe landscape of cognitive function in recovered COVID-19 patients
Zhou, H., Lu, S., Chen, J., Wei, N., Wang, D., Lyu, H., Shi, C., & Hu, S. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.06.022 · Cited by 440 · cited 2×
“show higher symptoms of depression and impairments in measures of sustained and selective attention, both of which are associated with activation of the immune-inflammatory system (Mazza et al., 2020; Zhou et al., 2020).”
BackgroundMolendijk, M. L., Bus, B. A. A., Spinhoven, P., Penninx, B. W. J. H., Kenis, G., Prickaerts, J., Voshaar, R. O., & Elzinga, B. M. (2011) · Molecular Psychiatry · doi:10.1038/mp.2010.98 · Cited by 437 · cited 1×
“Yet, the lower BDNF protein levels and altered epigenetic regulation observed in the blood of MDD patients suggest an overall net reduction of its signalling (Kurita, Nishino, Kato, Numata, & Sato, 2012; Molendijk et al., 2011, 2014; Van den Berg et al., 2020).”
BackgroundDSM-5 and RDoC: progress in psychiatry research?
Casey, B. J., Craddock, N., Cuthbert, B. N., Hyman, S. E., Lee, F. S., & Ressler, K. J. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3621 · Cited by 434 · cited 1×
“Each domain reflects a dysfunctional brain system and they together should be able to better explain the vast and complex symptomatologies and comorbidities of DSM-5 conditions, including MDD (Casey et al., 2013).”
BackgroundPreller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017) · Current Biology · doi:10.1016/j.cub.2016.12.030 · Cited by 402
Victor, T. A., Furey, M. L., Fromm, S. J., Öhman, A., & Drevets, W. C. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.144 · Cited by 400 · cited 1×
“In MDD, the amygdala shows increased reactivity to negative stimuli that correlates with negative affect (Victor et al., 2010; Hamilton et al., 2012).”
BackgroundVolumetric Analysis of the Prefrontal Cortex, Amygdala, and Hippocampus in Major Depression
Hastings, R. S., Parsey, R. V., Oquendo, M. A., Arango, V., & Mann, J. J. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300371 · Cited by 378
Hesselgrave, N., Troppoli, T. A., Wulff, A. B., Cole, A. B., & Thompson, S. M. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022489118 · Cited by 378 · cited 1×
“In line with our proposed model, the agonistic activity of psilocybin at this receptor might explain why pre-treatment with the 5HT2A antagonist ketanserin did not affect the antianhedonic effects of the drug observed in mice (Hesselgrave et al., 2021).”
Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2019.11.004 · Cited by 375 · cited 1×
“To support this idea, a study from Davis, Barrett, and Griffiths (2020) revealed a highly significant mediation effect of cognitive flexibility on the association between the acute subjective effects of psychedelics and I. Magaraggia et al. Neurobiology of Learning and Memory 183 (2021) 107467 a…”
ResultA High-Resolution In Vivo Atlas of the Human Brain's Serotonin System
Beliveau, V., Ganz, M., Feng, L., Ozenne, B., Højgaard, L., Fisher, P. M., Svarer, C., Greve, D. N., & Knudsen, G. M. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2830-16.2016 · Cited by 368 · cited 2×
“The 5-HT2AR is widely expressed throughout the cortex (Beliveau et al., 2017), and is the primary mediator of the acute subjective effects of psychedelics on cognition (Madsen et al., 2019; Nichols, 2016; Preller et al., 2017).”
BackgroundMcClintock, S. M., Husain, M. M., Greer, T. L., & Cullum, C. M. (2010) · Neuropsychology · doi:10.1037/a0017336 · Cited by 344
The Role of BDNF in Depression on the Basis of Its Location in the Neural Circuitry
Yu, H., & Chen, Z.-Y. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.184 · Cited by 343 · cited 1×
“A reduction of BDNF expression is present in the PFC and hippocampus of MDD patients whereas the opposite is true for the amygdala (Leite et al., 2018; Nunes et al., 2018; Qiao, An, Xu, & Ma, 2017; Sheldrick et al., 2017; Yu & Chen, 2011).”
The subjective effects of psychedelics may not be necessary for their enduring therapeutic effects
Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00192 · Cited by 329 · cited 2×
“Based on the lack of head twitch responses observed in mice after administration, the latter being a validated measure for the hallucinogenic property of drugs, Olson and colleagues claimed to have developed such compounds (Cameron et al., 2021; Olson, 2020).”
BackgroundFrodl, T., Reinhold, E., Koutsouleris, N., Reiser, M., & Meisenzahl, E. M. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.01.006 · Cited by 323
LSD enhances suggestibility in healthy volunteers
Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3714-z · Cited by 320 · cited 1×
“…they increased behaviors associated with cognitive flexibility, such as divergent and convergent creative thinking, suggestibility, and openness to new experiences (Carhart-Harris et al., 2015; Carhart-Harris, Bolstridge, et al., 2016; Mason, Mischler, Uthaug, & Kuypers, 2019; Uthaug et al., 2019).”
BackgroundBouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · cited 2×
“Moreover, regular ayahuasca users performed better than non-users in a set shifting task that requires cognitive flexibility (Bouso et al., 2012).”
BackgroundNeurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308 · cited 2×
“Moreover, reduction of hippocampal neuroplasticity is also observed by decrease in I. Magaraggia et al. Neurobiology of Learning and Memory 183 (2021) 107467 the number of newborn neurons in the dentate gyrus (DG), a process which is referred to as neurogenesis (Levy et al., 2018).”
BackgroundNeural regulation of the stress response: glucocorticoid feedback mechanisms
Herman, J. P., McKlveen, J. M., Solomon, M. B., Carvalho-Netto, E., & Myers, B. (2012) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2012007500041 · Cited by 307 · cited 1×
“Because of its stimulatory effects on the HPA axis, the sensitization of the amygdala creates a feed-forward mechanism for the stress response therefore leading to a steady inhibition of cortical and hippocampal neuroplasticity (Herman et al., 2012).”
Backgrounddos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306
Chronic Stress Causes Amygdala Hyperexcitability in Rodents
Rosenkranz, J. A., Venheim, E. R., & Padival, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.02.008 · Cited by 284
van Vreeswijk, M. F., & de Wilde, E. J. (2004) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(03)00194-3 · Cited by 280
Psilocybin – Summary of knowledge and new perspectives
Tylš, F., Páleníček, T., & Horáček, J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.12.006 · Cited by 276
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 4×
“Other studies in rodents reported an association between the neuroplastic effects of psychedelics and increased performance in fear extinction and learning and memory tasks (Morales-Garcia et al., 2020; Cameron et al., 2018; Catlow et al., 2013; Buchborn et al., 2014).”
BackgroundInfluentialLakshminarasimhan, H., & Chattarji, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030481 · Cited by 253
Holze, F., Vizeli, P., Ley, L., Müller, F., Dolder, P., Stocker, M., Duthaler, U., Varghese, N., Eckert, A., Borgwardt, S., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00883-6 · Cited by 245 · cited 1×
“In humans, LSD and ayahuasca acutely increased blood BNDF levels (Almeida et al., 2019; Holze et al., 2020).”
BackgroundCarhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.103309 · Cited by 237
The cognitive consequences of the COVID-19 epidemic: collateral damage?
Ritchie, K., Chan, D., & Watermeyer, T. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa069 · Cited by 226 · cited 1×
“Based on the observation that viruses, and especially coronaviruses, can lead to neuronal loss in the hippocampus (Ritchie et al., 2020), the neurogenesis-promoting effects of psychedelic compounds might be able to reverse these changes.”
BackgroundUthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4988-3 · Cited by 212
Culpepper, L., Lam, R. W., & McIntyre, R. S. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.tk16043ah5c · Cited by 211 · cited 2×
“In fact, patients with MDD show functional impairment within these constructs (Culpepper et al., 2017; Table 1).”
BackgroundLSD-Assisted Psychotherapy in Patients with Terminal Cancer
Grof, S., Goodman, L. E., Richards, W. A., & Kurland, A. A. (2017) · International Pharmacopsychiatry · doi:10.1159/000467984 · Cited by 209 · cited 1×
“Clinical evidence of the antidepressant effects of psychedelics During the so-called first wave of psychedelic research, scientists provided initial evidence of the efficacy of psychedelic-assisted psychotherapy at reducing symptoms of depression and anxiety in patients with life-threatening cancer (Grof et al., 1973;…”
BackgroundCell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
Kunugi, H., Hori, H., Adachi, N., & Numakawa, T. (2010) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2010.02135.x · Cited by 200 · cited 1×
“For example, the increase in glucocorticoid levels induced by chronic stress have been linked to reduced BDNF gene expression in MDD (Kunugi et al., 2010).”
BackgroundUthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., et al. (2019) · Psychopharmacology · doi:10.1007/s00213-019-05236-w · Cited by 197 · cited 1×
“…they increased behaviors associated with cognitive flexibility, such as divergent and convergent creative thinking, suggestibility, and openness to new experiences (Carhart-Harris et al., 2015; Carhart-Harris, Bolstridge, et al., 2016; Mason, Mischler, Uthaug, & Kuypers, 2019; Uthaug et al., 2019).”
BackgroundAlmeida, R. N. D., Galvão, A. C. D. M., da Silva, F. S., Silva, E. A. D. S., Palhano-Fontes, F., Maia-de-Oliveira, J. P., de Araújo, L.-S. B., Lobão-Soares, B., & Galvão-Coelho, N. L. (2019) · Frontiers in Psychology · doi:10.3389/fpsyg.2019.01234 · Cited by 177 · cited 2×
“Interestingly, these effects of ayahuasca correlated with a long-term reduction in depressive symptoms in MDD patients (Almeida et al., 2019).”
Depression and Cognitive Control across the Lifespan: a Systematic Review and Meta-Analysis
Dotson, V. M., McClintock, S. M., Verhaeghen, P., Kim, J. U., Draheim, A. A., Syzmkowicz, S. M., Gradone, A. M., Bogoian, H. R., & Wit, L. D. (2020) · Neuropsychology Review · doi:10.1007/s11065-020-09436-6 · Cited by 173
Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being
Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1580804 · Cited by 172 · cited 1×
“In fact, they increased behaviors associated with cognitive flexibility, such as divergent and convergent creative thinking, suggestibility, and openness to new experiences (Mason et al., 2019; CarhartHarris et al., 2015; Carhart-Harris et al., 2016a; Uthaug et al., 2019).”
BackgroundEffects of N,N-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171
Cameron, L. P., Benson, C. J., DeFelice, B. C., Fiehn, O., & Olson, D. E. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00692 · Cited by 168 · cited 1×
“, 2020a & 2020b) Promising results have been obtained also from a preclinical study in which intermittent administration of low non-hallucinogenic doses of DMT increased fear extinction in rats (Cameron et al, 2018; Cameron et al., 2019).”
BackgroundNichols, C. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00405-5 · Cited by 163 · cited 2×
“Moreover, treatment with psilocybin and LSD led to an overexpression of neuroplasticity-related genes in this area (Jefsen, Elfving, Wegener, & Müller, 2020; Nichols & Sanders-Bush, 2002).”
BackgroundMorales-Garcia, J. A., Calleja-Conde, J., Lopez-Moreno, J. A., Alonso-Gil, S., Sanz-SanCristobal, M., Riba, J., & Perez-Castillo, A. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-01011-0 · Cited by 138 · cited 3×
“…in rodents reported an association between the neuroplastic effects of psychedelics and increased performance in fear extinction and learning and memory tasks (Buchborn, Schröder, Höllt, & Grecksch, 2014; Cameron, Benson, Dunlap, & Olson, 2018; Catlow et al., 2013; Morales-Garcia et al., 2020).”
BackgroundAyahuasca’s ‘afterglow’: improved mindfulness and cognitive flexibility in ayahuasca drinkers
Murphy-Beiner, A., & Soar, K. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05445-3 · Cited by 135
Presynaptic serotonin 2A receptors modulate thalamocortical plasticity and associative learning
Barre, A., Berthoux, C., De Bundel, D., Valjent, E., Bockaert, J., Marin, P., & Bécamel, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525586113 · Cited by 135 · cited 2×
“In the PFC, an increase in structural and synaptic plasticity is observed after treatment with psychedelics (Barre et al., 2016; Berthoux, Barre, Bockaert, Marin, & Bécamel, 2019; Ly et al., 2018).”
Low doses of LSD acutely increase BDNF blood plasma levels in healthy volunteers
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00099 · Cited by 131 · cited 2×
“…increased mature BDNF levels in healthy humans and, contrary to the effects of hallucinogenic doses, it improved measures of sustained attention (Hutten et al., 2020a, 2020b) Promising results have been obtained also from a preclinical study in which intermittent administration of low…”
BackgroundChanges in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca
Galvão-Coelho, N. L., de Menezes Galvão, A. C., de Almeida, R. N., Palhano-Fontes, F., Campos Braga, I., Lobão Soares, B., Maia-de-Oliveira, J. P., Perkins, D., Sarris, J., & de Araujo, D. B. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881120936486 · Cited by 128 · cited 2×
“…also indirectly stimulate neuroplasticity by reducing I. Magaraggia et al. Neurobiology of Learning and Memory 183 (2021) 107467 the activation of the immune system and the HPA-axis in MDD (da Silva et al., 2019; de Menezes Galvão et al., 2018; Galvão-Coelho et al., 2020; Uthaug et al., 2020).”
BackgroundJefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.10.002 · Cited by 123 · cited 3×
“…increased mature BDNF levels in healthy humans and, contrary to the effects of hallucinogenic doses, it improved measures of sustained attention (Hutten et al., 2020a, 2020b) Promising results have been obtained also from a preclinical study in which intermittent administration of low…”
BackgroundTransient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123 · cited 5×
“Like psychedelics, there is strong evidence showing that the underlying mechanism of these effects involves the stimulation of cortical neuroplasticity and hippocampal neurogenesis (Ly et al., 2018, 2020; Murrough et al., 2013).”
BackgroundInfluentialUthaug, M. V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020) · Psychopharmacology · doi:10.1007/s00213-019-05414-w · Cited by 117
Wallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97 · cited 1×
“Relevant in this regard is also that chronic administration of vortioxetine reversed stress-induced cognitive deficits, such as impaired reversal learning and fear memory and extinction, in rodents (Wallace et al., 2014; Hatherall et al., 2017).”
BackgroundSubregional hippocampal deformations in major depressive disorder
Cole, J., Toga, A. W., Hojatkashani, C., Thompson, P., Costafreda, S. G., Cleare, A. J., Williams, S. C. R., Bullmore, E. T., Scott, J. L., & Mitterschiffthaler, M. T. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.03.004 · Cited by 94 · cited 2×
“Similarly to the PFC, the hippocampus of MDD patients shows signs of atrophy, including reduced size, activity, and levels of neurotrophic factors (Cole et al., 2010; Nunes et al., 2018; Sheldrick, Camara, Ilieva, Riederer, & Michel, 2017; Frodl et al., 2002).”
BackgroundMethodLima da Cruz, R. V., Moulin, T. C., Petiz, L. L., & Leão, R. N. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00312 · Cited by 84
Colaço, C. S., Alves, S. S., Nolli, L. M., Pinheiro, W. O., de Oliveira, D. G. R., Santos, B. W. L., Pic-Taylor, A., Mortari, M. R., & Caldas, E. D. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00547-w · Cited by 58 · cited 1×
“For example, a study performed in rats showed an increase in hippocampal and cortical BNDF levels after administration of ayahuasca (Colaço et al., 2020).”
BackgroundProspective memory deficits in patients with depression: A meta-analysis
Zhou, F.-C., Wang, Y.-Y., Zheng, W., Zhang, Q., Ungvari, G. S., Ng, C. H., Zhang, J., & Xiang, Y.-T. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.042 · Cited by 52
Samara, Z., Evers, E. A. T., Peeters, F., Uylings, H. B. M., Rajkowska, G., Ramaekers, J. G., & Stiers, P. (2018) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2018.01.004 · Cited by 40 · cited 3×
“observation, changes in inferior parietal lobule activity have been associated with the reduction in attentional biases by cognitive behavioural therapy in MDD (Samara et al., 2018).”
BackgroundResultInfluentialJensen, A. A., Halberstadt, A. L., Märcher-Rørsted, E., Odland, A. U., Chatha, M., Speth, N., Liebscher, G., Hansen, M., Bräuner-Osborne, H., Palner, M., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113979 · Cited by 28
Cited by
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 325
Towards an understanding of psychedelic-induced neuroplasticity
Calder, A. E., & Hasler, G. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01389-z · Cited by 313
Neuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Aaronson, S. T., van der Vaart, A., Miller, T., LaPratt, J., Swartz, K., Shoultz, A., Lauterbach, M., Sackeim, H. A., & Suppes, T. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.4685 · Cited by 114
Kurzbaum, E., Páleníček, T., Sharchaton, A., Azerrad, S., & Dekel, Y. (2025) · Journal of Fungi · doi:10.3390/jof11020099 · Cited by 15
Metadata
- Authors
- Magaraggia, I., Kuiperes, Z., & Schreiber, R.
- Venue
- Neurobiology of Learning and Memory
- Publisher
- Elsevier BV
- Published
- 2021-09
- Volume
- 183
- Pages
- 107467
- ISSN
- 1074-7427 (ISSN-L)
- OpenAlex
- W3165684389
- Cited by
- 49
- References
- 97
- FWCI
- 5.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.